Table 1 Characteristics of studies selected in the meta-analysis
Study | Year | NOS | Journal | Region | Total number | TET2m | Median age | Detecting method | Data type | Therapy regimen | Cohort type |
|---|---|---|---|---|---|---|---|---|---|---|---|
Wahab | 2009 | 7 | Blood | America | 91 | 11 | 65 | Unknown | Calculated from K-M curves | Unknown | AML |
Nibourel | 2010 | 6 | Blood | France | 111 | 19 | 43 | Direct sequencing | Calculated from K-M curves | Anthracycline-cytosine arabinoside induction treatment followed by HDAC consolidation or allo-HSCT | AML |
Metzeler | 2011 | 9 | Journal of Clinical Oncology | America | 418 | 95 | > 60 | Direct sequencing | Calculated from K-M curves | Standard intensive therapy | CN-AML |
Kosmider | 2011 | 7 | Haematologica | France | 247 | 49 | 66 | Direct sequencing | Unitivariate or calculated from K-M curves | Intensive chemotherapy with anthracycline-cytarabine | s-AML |
Chou | 2011 | 7 | Blood | China | 486 | 64 | 51.5 | Unknown | Multivariate and calculated from K-M curves | Standard intensive therapy or palliativecare or low-dose chemotherapy | AML |
Patel | 2012 | 8 | The New England Journal of Medicine | America | 391 | 33 | < 60 | Direct sequencing | Calculated from K-M curves | Induction therapy with high or standard dose of DNR | AML |
Weissmann | 2012 | 7 | Leukemia | Germany | 318 | 87 | 66.4 | Next-generation sequencing | Calculated from K-M curves | Unknown | AML |
Gaidzik | 2012 | 8 | Journal of Clinical Oncology | Germany | 783 | 60 | < 60 | Direct sequencing | Calculated from K-M curves | Double induction therapy | AML |
Renneville | 2014 | 6 | Oncotarget | France | 139 | 19 | 62 | Direct sequencing | Univariate | Standard front-line chemotherapy with or without low-dose gemtuzumab ozogamicin | CN-AML |
Damm | 2014 | 8 | Genes Chromosomes and Cancer | France and Germany | 215 | 13 | < 60 | Direct sequencing | multivariate | Intensive double induction and consolidation therapy | CN-AML |
Tian | 2014 | 7 | International Journal of Hematology | Asia | 373 | 60 | 45 | Direct sequencing | Calculated from K-M curves | Standard induction therapy followed by consolidation of HDAC or allo-HSCT | CN-AML |
S.Ohgami | 2015 | 7 | Modern Pathology | America | 93 | 6 | 55 | Next-generation sequencing | Muitivariate | Standard induction therapy with cytarabine and danorubicin or idarubicin | AML |
Ahn | 2015 | 9 | Haematologica | Multiple region | 407 | 54 | 52 | Direct sequencing | Muitivariate | Standard induction therapy | CN-AML |
Kao | 2015 | 8 | Oncotarget | China | 98 | 18 | 55 | Direct sequencing | Calculated from K-M curves | Standard intensive therapy with daunomycin and cytarabine | AML with MLL-PTD |
Cher | 2016 | 8 | Blood Cancer Journal | China | 96 | 8 | 41 | Next-generation sequencing | Multivariate and univariate | Induction chemotherapy comprising cytarabine and daunorubicin with consolidation therapy comprising HDAC or allo-HSCT | CBF-AML |
Lin | 2016 | 9 | Cancer Medicine | China | 112 | 12 | 42.6 | Next-generation sequencing | Multivariate | Standard therapy with or without allo-HSCT | AML |